MA52504A - Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations - Google Patents
Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisationsInfo
- Publication number
- MA52504A MA52504A MA052504A MA52504A MA52504A MA 52504 A MA52504 A MA 52504A MA 052504 A MA052504 A MA 052504A MA 52504 A MA52504 A MA 52504A MA 52504 A MA52504 A MA 52504A
- Authority
- MA
- Morocco
- Prior art keywords
- type
- binding proteins
- receptor binding
- cannabinoid receptor
- cannabinoid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862664882P | 2018-04-30 | 2018-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52504A true MA52504A (fr) | 2021-04-28 |
Family
ID=67396963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052504A MA52504A (fr) | 2018-04-30 | 2019-04-29 | Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations |
Country Status (20)
Country | Link |
---|---|
US (2) | US20220396620A1 (fr) |
EP (1) | EP3787746A1 (fr) |
JP (2) | JP7431750B2 (fr) |
KR (1) | KR20210005051A (fr) |
CN (1) | CN112218684A (fr) |
AR (1) | AR114436A1 (fr) |
AU (1) | AU2019264029A1 (fr) |
BR (1) | BR112020022035A2 (fr) |
CA (1) | CA3098416A1 (fr) |
CL (1) | CL2020002793A1 (fr) |
CO (1) | CO2020014681A2 (fr) |
EA (1) | EA202092593A1 (fr) |
EC (1) | ECSP20076576A (fr) |
MA (1) | MA52504A (fr) |
MX (1) | MX2020011498A (fr) |
PE (1) | PE20210419A1 (fr) |
PH (1) | PH12020551805A1 (fr) |
SG (1) | SG11202010388SA (fr) |
TW (1) | TW202003549A (fr) |
WO (1) | WO2019211665A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20210419A1 (es) | 2018-04-30 | 2021-03-08 | Takeda Pharmaceuticals Co | Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas |
WO2023242843A1 (fr) * | 2022-06-17 | 2023-12-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Périphérisation d'antagonistes du récepteur cannabinoïde-1 à action centrale par des nanoparticules pour le traitement d'affections associées au métabolisme |
WO2024022478A1 (fr) * | 2022-07-28 | 2024-02-01 | 长春金赛药业有限责任公司 | Anticorps se liant au récepteur cannabinoïde cb1 et son utilisation |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0098110B1 (fr) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Composition à action prolongée |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
CA2069530A1 (fr) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Trousse de reactifs pour dosages immunologiques |
WO1992022653A1 (fr) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Procede de production d'anticorps humanises |
CA2103887C (fr) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2297209A4 (fr) | 2008-06-03 | 2012-08-01 | Abbott Lab | Immunoglobulines à deux domaines variables et leurs utilisations |
CA2915386A1 (fr) * | 2013-06-26 | 2014-12-31 | Amgen Inc. | Proteines de liaison a l'antigene se liant aux recepteurs cb1 et leurs utilisations |
WO2015148984A2 (fr) * | 2014-03-27 | 2015-10-01 | Ruiyi Inc. | Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain |
US10277406B1 (en) * | 2014-09-05 | 2019-04-30 | Digicert, Inc. | Authentication process for issuing sequence of short-lived digital certificates |
US10034865B2 (en) | 2015-09-10 | 2018-07-31 | Kashiv Pharma, Llc | Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof |
AU2016330471B2 (en) * | 2015-09-30 | 2022-09-29 | Bird Rock Bio, Inc. | Antibodies that bind human cannabinoid 1 (CB1) receptor |
PE20210419A1 (es) | 2018-04-30 | 2021-03-08 | Takeda Pharmaceuticals Co | Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas |
-
2019
- 2019-04-29 PE PE2020001750A patent/PE20210419A1/es unknown
- 2019-04-29 AR ARP190101123A patent/AR114436A1/es unknown
- 2019-04-29 SG SG11202010388SA patent/SG11202010388SA/en unknown
- 2019-04-29 EA EA202092593A patent/EA202092593A1/ru unknown
- 2019-04-29 KR KR1020207032056A patent/KR20210005051A/ko unknown
- 2019-04-29 CA CA3098416A patent/CA3098416A1/fr active Pending
- 2019-04-29 EP EP19742647.1A patent/EP3787746A1/fr active Pending
- 2019-04-29 JP JP2020558493A patent/JP7431750B2/ja active Active
- 2019-04-29 WO PCT/IB2019/000503 patent/WO2019211665A1/fr active Search and Examination
- 2019-04-29 BR BR112020022035-3A patent/BR112020022035A2/pt unknown
- 2019-04-29 MA MA052504A patent/MA52504A/fr unknown
- 2019-04-29 CN CN201980029451.9A patent/CN112218684A/zh active Pending
- 2019-04-29 US US17/052,048 patent/US20220396620A1/en active Pending
- 2019-04-29 AU AU2019264029A patent/AU2019264029A1/en active Pending
- 2019-04-29 MX MX2020011498A patent/MX2020011498A/es unknown
- 2019-04-30 TW TW108115125A patent/TW202003549A/zh unknown
-
2020
- 2020-10-27 CL CL2020002793A patent/CL2020002793A1/es unknown
- 2020-10-29 PH PH12020551805A patent/PH12020551805A1/en unknown
- 2020-11-26 CO CONC2020/0014681A patent/CO2020014681A2/es unknown
- 2020-11-27 EC ECSENADI202076576A patent/ECSP20076576A/es unknown
-
2021
- 2021-03-16 US US17/203,291 patent/US11746155B2/en active Active
-
2024
- 2024-02-01 JP JP2024014317A patent/JP2024059646A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210005051A (ko) | 2021-01-13 |
JP7431750B2 (ja) | 2024-02-15 |
CL2020002793A1 (es) | 2021-02-12 |
MX2020011498A (es) | 2021-01-29 |
EP3787746A1 (fr) | 2021-03-10 |
TW202003549A (zh) | 2020-01-16 |
SG11202010388SA (en) | 2020-11-27 |
US11746155B2 (en) | 2023-09-05 |
US20210198358A1 (en) | 2021-07-01 |
CO2020014681A2 (es) | 2020-12-10 |
EA202092593A1 (ru) | 2021-02-12 |
WO2019211665A1 (fr) | 2019-11-07 |
PE20210419A1 (es) | 2021-03-08 |
PH12020551805A1 (en) | 2021-07-26 |
CA3098416A1 (fr) | 2019-11-07 |
CN112218684A (zh) | 2021-01-12 |
ECSP20076576A (es) | 2021-12-30 |
JP2021525059A (ja) | 2021-09-24 |
BR112020022035A2 (pt) | 2021-02-02 |
AU2019264029A1 (en) | 2020-11-19 |
AR114436A1 (es) | 2020-09-02 |
JP2024059646A (ja) | 2024-05-01 |
US20220396620A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52273A (fr) | Protéines de liaison à un antigène anti-trem2 et leurs utilisations | |
MA44885A (fr) | Protéines de liaison bispécifiques et leurs utilisations | |
MA42808A (fr) | Anticorps de liaison à l'il-8 et leurs utilisations | |
MA55627A (fr) | Agonistes de glp-1r et leurs utilisations | |
MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
MA54555A (fr) | Agonistes de glp-1r et leurs utilisations | |
MA46789A (fr) | Molécules de liaison spécifiques d'asct2 et leurs utilisations | |
MA52504A (fr) | Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations | |
MA52785A (fr) | Molécules de liaison dirigées contre bcma et leurs utilisations | |
MA52777A (fr) | Agents de liaison psma et utilisations correspondantes | |
MA42059A (fr) | Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci | |
MA47113A (fr) | Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation | |
MA46359A (fr) | Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation | |
MA49457A (fr) | Molécules d'anticorps se liant à cd73 et leurs utilisations | |
MA43816A (fr) | Protéines de liaison inductibles et méthodes d'utilisation | |
MA44060A (fr) | Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations | |
MA46917A (fr) | Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation | |
DK3476399T3 (da) | Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf | |
MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
MA49512A (fr) | Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation | |
MA50255A (fr) | Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1) | |
MA51230A (fr) | Protéines f rsv stabilisées et leurs utilisations | |
MA53665A (fr) | Agonistes du récepteur farnésoïde x et leurs utilisations | |
DK3930847T5 (da) | Anti-mertk-antistoffer med høj affinitet og anvendelser deraf | |
MA56029A (fr) | Molécules de liaison au tigit et pd-1/tigit |